Clinical Research Directory
Browse clinical research sites, groups, and studies.
Beijing Protocol in Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Sponsor: Peking University People's Hospital
Summary
The aim of the study is to evaluate the efficacy and safety of Beijing protocol in malignant haematologic disease patients receiving more than 5/10 HLA-mismatched allo-HSCT.
Official title: The Safety and Efficiency of Beijing Protocol in Malignant Hematologic Disease Patients Receiving More Than 5/10 HLA-mismatched Allo-HSCT
Key Details
Gender
All
Age Range
Any - 70 Years
Study Type
OBSERVATIONAL
Enrollment
20
Start Date
2023-06-01
Completion Date
2026-05-31
Last Updated
2023-06-27
Healthy Volunteers
No
Interventions
Beijing protocol
For patients \<55 years and HCT-CI≤ 3：Ara-C(4g/m2/day,-9 days),Bu(9.6mg/kg,-8 days to -6 days),Cy(1,800mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days) For patients ≥ 55 years or HCI-CI\>3：Ara-C(2g/m2/day,-10 days to -9 days),Bu(9.6mg/kg,-8 days to -6 days),Flu(30mg/m2/day,-6 days to -2 days),Cy(1,000mg/m2/day,-5 days to -4 days),semustine(250mg/m2,-3 days),ATG(7.5-10 mg/kg,-5 to -2 days).
Locations (1)
Deparment of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China